🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,385

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

32 results for “Acadia” Clear

  1. ACP-204

    Acadia Pharmaceuticals B.V.

    Lewy Body Dementia Psychosis

    phase 3 small molecule active

    2 trials

  2. ACP-204

    Acadia Pharmaceuticals B.V.

    Alzheimer's Disease Psychosis

    phase 3 small molecule active

    2 trials

  3. Carbetocin

    Acadia Pharmaceuticals B.V.

    Hyperphagia in Prader-Willi Syndrome

    phase 3 small molecule active

    2 trials

  4. Pimavanserin

    Acadia Pharmaceuticals B.V.

    Neuropsychiatric Symptoms Related to Neurodegenerative Disease

    phase 3 small molecule completed

    2 trials

  5. Pimavanserin

    Acadia Pharmaceuticals B.V.

    Adjunctive Treatment of Major Depressive Disorder

    phase 3 small molecule terminated

    3 trials

  6. Pimavanserin

    Acadia Pharmaceuticals B.V.

    Schizophrenia

    phase 3 small molecule completed

    4 trials

  7. Pimavanserin

    Acadia Pharmaceuticals B.V.

    Irritability Associated With Autism Spectrum Disorder

    phase 3 small molecule completed

    2 trials

  8. Pimavanserin tartrate (ACP-103)

    Acadia Pharmaceuticals B.V.

    Parkinson's Disease Psychosis

    phase 3 small molecule completed

    4 trials

  9. Placebo

    Acadia Pharmaceuticals B.V.

    Dementia-related Psychosis

    phase 3 small molecule completed

    1 trial

  10. Trofinetide

    Acadia Pharmaceuticals B.V.

    Rett Syndrome

    phase 3 small molecule completed

    4 trials

  11. pimavanserin tartrate

    Acadia Pharmaceuticals B.V.

    Parkinson's Disease Psychosis

    phase 3 small molecule completed

    1 trial

  12. ACP-044 Dose A

    Acadia Pharmaceuticals B.V.

    Acute Postoperative Pain

    phase 2 small molecule completed

    1 trial

  13. ACP-044 Dose A

    Acadia Pharmaceuticals B.V.

    Osteoarthritis Pain

    phase 2 small molecule terminated

    1 trial

  14. ACP-103

    Acadia Pharmaceuticals B.V.

    Hallucinations

    phase 2 small molecule completed

    1 trial

  15. ACP-103

    Acadia Pharmaceuticals B.V.

    Schizophrenia

    phase 2 small molecule completed

    1 trial

  16. ACP-104

    Acadia Pharmaceuticals B.V.

    Schizophrenia

    phase 2 small molecule completed

    2 trials

  17. ACP-211

    Acadia Pharmaceuticals B.V.

    Major Depressive Disorder (MDD)

    phase 2 small molecule active

    1 trial

  18. Active drug: pimavanserin 17mg (2 strength tablets)

    Acadia Pharmaceuticals B.V.

    Parkinson Disease

    phase 2 small molecule completed

    1 trial

  19. Pimavanserin

    Acadia Pharmaceuticals B.V.

    Parkinson's Disease

    phase 2 small molecule terminated

    1 trial

  20. Pimavanserin

    Acadia Pharmaceuticals B.V.

    Agitation and Aggression in Alzheimer's Disease

    phase 2 small molecule completed

    1 trial

  21. Pimavanserin

    Acadia Pharmaceuticals B.V.

    Treatment of Depression in Adults With Parkinson's Disease (PD)

    phase 2 small molecule completed

    1 trial

  22. Pimavanserin 34 mg

    Acadia Pharmaceuticals B.V.

    Agitation and Aggression in Alzheimer's Disease

    phase 2 small molecule terminated

    1 trial

  23. Pimavanserin 34 mg

    Acadia Pharmaceuticals B.V.

    Intermittent Explosive Disorder

    phase 2 small molecule active

    1 trial

  24. Pimavanserin 34 milligrams (MG) [Nuplazid]

    Acadia Pharmaceuticals B.V.

    Schizophrenia

    phase 2 small molecule terminated

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources